CIBER-BBN’s exploitable technology patent portfolio is available to companies and organizations to promote its transfer to the industrial sector, generate collaborative technological development projects and favour the use of the research results.
Each of the “technological specification sheets” describes a technology, its industrial application and innovative advantages, among other aspects. Said information can be expanded through the contact shown in each of them.
CIBERER is making available its technologyl range of patents to be exploited:
Here you will find our offers and requests for technology that are available for collaboration with companies. If you need any further information or have a particular technological issue to address, please contact us at firstname.lastname@example.org. We are open to different kinds of collaboration.
Quick method to assess if different isolates of M. Tuberculosis have the same clone origin and if they are resistant to rifampicin and isoniazid
Based in IS6110 (Gold standard), offers quick results (few hours), is automated, standardized and reproducible. If widely adopted, this technology would allow better control of TB. The technology can be used to identify strains resistant to rifampicin and isoniazid and can be extended to other bacteria with specific IS.
High reliability prediction of fluid/vascular responses and estimation of pleural pressure changes in patients
The non-invasive method allows the prediction of patient's response to intravenous administration of fluid or to evaluate the state of arterial tone or the change of pleural pressure due to respiration. It allows the optimization of hemodynamic monitoring. This evaluation can be carried out in patients under mechanical ventilation or in punctual monitoring, even in patients with cardiac or respiratory arrhythmias.
Detection of Tuberculosis in urine samples by a specific metabolic signature.
A set of metabolic biomarkers, whose relative level can diagnose tuberculosis in urine samples. A quick and non invasive method to identify and classify patients with a high specificity and sensitivity and with a tuberculosis predictive value of 100%.
Early prognosis of Tako-Tsubo cardiomyopathy in patients with aneurysmal subarachnoid haemorrhage.
Combined quantification of molecules in blood able of predict, with 100% efficiency from admission in emergency, if a patient with aneurysmal subarachnoid haemorrhage will develop Tako-Tsubo cardiomyopathy.
Mortality prediction in COVID-19 patients.
Quantification of a Coronavirus structural protein in plasma, serum or blood samples that enables to differentiate patients with bad prognosis and/or higher mortality risk candidates for receiving an antiviral therapy or further monitoring.
In this area you can consult our technology supply and demand available for cooperation with business.
CIBEROBN has the following Technology Range available for you:
Technology range of the CIBEREHD:
En este espacio ofrecemos la Oferta Tecnológica del CIBERCV: